References


523. Thrainsdottir IS, Aspelund T, Hardarson T, Malmberg K, Sigurdsson G, 
Solang L, Malmberg K, Rydén L. Diabetes mellitus and congestive heart 

525. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect 
of ramipril on mortality and morbidity of survivors of acute myocardial 

527. Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D 
et al. Effects of the angiotensin converting enzyme inhibitor enalapril 
on the long-term progression of left ventricular dysfunction in patients with 

529. Konstam MA, Patton RD, Thomas I, Ramahi T, La Bresh K, Goldman S 
et al. Effects of losartan and captopril on left ventricular volumes in 
elderly patients with heart failure: results of the ELITE ventricular func-

531. Rydén L, Armstrong PW, Cleland JG et al. Effects of enalapril on survival in patients with 

533. Moye LA, Pfeffer MA, Wun CC et al. Effects of spironolactone on morbidity and mortality in patients with 

535. Parsonage WA, Hetmanski D, Cowley AJ. Beneficial haemodynamic 

537. McNulty PH, Pfuß S, Deckelbaum LI. Effect of plasma insulin level on 

539. Smooke S, Howrich TB, Fonarow GC. Insulin-treated diabetes is associ-
ated with a marked increase in mortality in patients with advanced 

541. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Palensky J, 
Wittes J. For the Randomized Aldactone Evaluation Study Investigators. 
Effects of spironolactone on morbidity and mortality in patients with 

543. Deedwania PC, Giles TD, Klibaner M, Ghali JK, Herlitz J, Hildebrandt P, 
Kjevikshus J, Spinar J, Vitovec J, Stanbrook H, Wikström J; MERIT-HF 
Study Group. Efficacy, safety and tolerability of metoprolol CR/XL in 
patients with diabetes and chronic heart failure: experiences from 

Carvedilol Prospective Randomized Cumulative Survival Study 
Group. Effect of carvedilol on survival in severe chronic heart failure. 

547. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanprath P, 
Komajda M et al. for the COMET Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart 
failure in the Carvedilol Or Metoprolol European Trial (COMET): random-

549. McNulty PH, Pfuß S, Deckelbaum LI. Effect of plasma insulin level on 

551. Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in 

Short- and long-term beneficial effects of trimetazidine in patients with 

555. Thrainsdottir IS, von Bibra H, Malmberg K, Rydén L. Effects of trimet-
azidine on left ventricular function in patients with type 2 diabetes and 

557. Lewis JF, DaCosta M, Wargowich T, Stacpoole P. Effects of dichloroace-
potassium infusion on chronic ischaemic left ventricular dysfunction. 

559. American Diabetes Association: Clinical Practice Recommendations 

561. Levy S, Maarek M, Coumel P. Independent risk factors for atrial fibrillation in a population-based 

Prevalence of atrial fibrillation in elderly subjects (The Cardiovascular Health Study). 

fibrillation: the An-Ticoagulation and Risk Factors in Atrial fibrillation (ATRIA) Study. 

567. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Silent myocardial ischae-
mic/Miss silent myocardial ischaemia VE, Rautaharju PM. Prevalence of 
atrial fibrillation in elderly subjects (The Cardiovascular Health Study). 

569. Psaty BM, Manolio TA, Küller LH, Kronnal RA, Cushman M, Fried LP, 
White R, Furberg CD, Rautaharju PM. Incidence of and risk factors for 

571. Levy S, Maarek M, Cournel P et al. Characterization of different subsets of 
atrial fibrillation in general practice in France: the ALFA study. The 

573. Krah AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural 
history of atrial fibrillation: incidence, risk factors, and prognosis in the 

Independent risk factors for atrial fibrillation in a population-based 

fibrillation: the An-Ticoagulation and Risk Factors in Atrial fibrillation (ATRIA) Study. 

579. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of 
antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. *Arch Intern Med* 1994; 154: 
1449–1457.


